
Open Your Free Demat Account
Enjoy low brokerage on delivery trades
BAJAJ BROKING
Cipla recorded ₹1,291.61 crore in net profit and ₹6,957.47 crore in revenue for Q1 FY25–26. Performance was driven by strong pharmaceutical growth and improved contribution from new ventures, maintaining a stable financial trajectory with consistent earnings momentum.
Revenue from operations: ₹6,957.47 crore
Total income: ₹7,216.03 crore
Profit before tax: ₹1,769.93 crore
Net profit (after tax): ₹1,291.61 crore
Basic earnings per share (EPS): ₹16.07
Segment revenue – Pharmaceuticals: ₹6,579.42 crore
Segment revenue – New ventures: ₹443.70 crore
Segment result – Pharmaceuticals: ₹1,727.22 crore
Segment result – New ventures: ₹56.76 crore
Cipla recorded a steady quarterly performance driven by a strong pharmaceutical segment and growing contribution from new business initiatives. Operational revenue remained stable, while expenses were effectively managed across verticals.
Financial Summary – ₹ in crore
Particulars | Q1 FY26 | Q4 FY25 | Q1 FY25 |
Revenue from operations | 6,957.47 | 6,729.69 | 6,693.94 |
Other income | 258.56 | 289.46 | 160.19 |
Total income | 7,216.03 | 7,019.15 | 6,854.13 |
Total expenses | 5,446.10 | 5,514.85 | 5,242.77 |
Profit before share of associates and tax | 1,769.93 | 1,504.30 | 1,611.36 |
Tax expense (net) | 477.88 | 279.28 | 365.90 |
Net profit for the period | 1,291.61 | 1,214.14 | 1,275.46 |
Total comprehensive income | 1,373.02 | 1,266.01 | 1,246.20 |
Basic earnings per share (₹2 face value) | ₹16.07 | ₹15.13 | ₹14.58 |
1. Revenue by Segment
Cipla operates through two major reporting segments: Pharmaceuticals and New Ventures.
Segment | Q1 FY26 Revenue (₹ Cr) | Q1 FY25 Revenue (₹ Cr) |
Pharmaceuticals | 6,579.42 | 6,389.30 |
New Ventures | 443.70 | 353.98 |
Total Revenue | 7,023.12 | 6,743.28 |
Inter-segment adj. | 65.65 | 49.34 |
Net Revenue | 6,957.47 | 6,693.94 |
2. Segment Results
Segment | Q1 FY26 Result (₹ Cr) | Q1 FY25 Result (₹ Cr) |
Pharmaceuticals | 1,727.22 | 1,630.64 |
New Ventures | 56.76 | (1.33) |
Finance Costs | 14.05 | 17.95 |
PBT (Pre-tax) | 1,769.93 | 1,611.36 |
The pharmaceutical business remains the primary contributor to revenue and profit, while new ventures returned to profitability this quarter.
Commenting on the Q1 results Umang Vohra, MD and Global CEO of Cipla quoted “I am pleased to share that we continue to make considerable progress across our focused markets. In Q3FY25, we delivered growth across all our various geographies, despite of a supply challenge in the U.S. We recorded a revenue growth of 8% over last year with a highest-ever EBITDA margin of 28.1%, driven by mix and other operational efficiencies. Our One-India business grew at a healthy 10% YoY. Key therapies in Branded Prescription business continued to outpace the market growth, Trade Generics business growth trajectory is back on track and Anchor brands of Consumer Health Business maintained leadership position. With a positive traction in our differentiated assets, the US business posted a revenue of $ 226 Mn. In South Africa, we recorded a solid growth of 21% YoY in local currency terms. Emerging Markets and Europe delivered a substantial revenue growth of 20% YoY on the back of deep market focus strategy.”
For a complete overview of all upcoming and past earnings reports, check the Quarterly Results Calendar 2025.
Source - Q1 FY25-26 Quarterly Results Uploaded on BSE dated 25 July 2025
Share this article:
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading